MK-2206

Small molecule targets AKT1, AKT2, AKT3 via inhibition

Developed for: HER2 positive breast carcinoma · cancer · breast cancer · chronic lymphocytic leukemia/small lymphocytic lymphoma · estrogen-receptor positive breast cancer · adult hepatocellular carcinoma · anaplastic large cell lymphoma · breast carcinoma
+104 more
· diffuse large B-cell lymphoma · extranodal nasal NK/T cell lymphoma · female breast carcinoma · gastroesophageal junction adenocarcinoma · grade III lymphomatoid granulomatosis · hairy cell leukemia · Hodgkins lymphoma · intraocular lymphoma · large-cell immunoblastic lymphoma · male breast carcinoma · mantle cell lymphoma · mycosis fungoides and variants · progesterone-receptor positive breast cancer · small intestine lymphoma · splenic marginal zone lymphoma · triple-negative breast carcinoma · Waldenstrom macroglobulinemia · acute erythroid leukemia · acute megakaryoblastic leukemia in adult · acute myeloblastic leukemia with maturation · acute myeloblastic leukemia without maturation · acute myeloid leukemia with 11q23 abnormalities · acute myeloid leukemia with minimal differentiation · acute myeloid leukemia with t(8;21)(q22;q22) translocation · acute myeloid leukemia, del(5q31-q32) · acute myeloid leukemia, inv(16)(p13.1;q22) · acute myeloid leukemia, t(16;16)(p13.1;q22) · acute myelomonocytic leukemia M4 · acute undifferentiated leukemia · adenosquamous lung carcinoma · adult acute monocytic leukemia · adult T-cell leukemia/lymphoma · aggressive NK-cell leukemia · angioimmunoblastic T-cell lymphoma · atypical chronic myeloid leukemia, BCR-ABL1 negative · Burkitt lymphoma · cancer of unknown primary site · CD4+/CD56+ hematodermic neoplasm · central nervous system non-hodgkin lymphoma · childhood acute lymphoblastic leukemia · childhood acute myeloid leukemia · cholangiocarcinoma · chronic eosinophilic leukemia · chronic myeloid leukemia · chronic neutrophilic leukemia · colon carcinoma · colon mucinous adenocarcinoma · colon signet ring cell adenocarcinoma · colorectal neoplasm · cutaneous melanoma · diffuse gastric adenocarcinoma · distal biliary tract carcinoma · endometrial adenosquamous carcinoma · endometrial clear cell adenocarcinoma · endometrial serous adenocarcinoma · esophageal cancer · estrogen-receptor negative breast cancer · fallopian tube carcinoma · gallbladder adenocarcinoma · gallbladder adenosquamous carcinoma · gallbladder carcinoma · gastric cancer · gastric intestinal type adenocarcinoma · hepatosplenic T-cell lymphoma · invasive breast carcinoma · juvenile myelomonocytic leukemia · lung adenocarcinoma · lung cancer · lung large cell carcinoma · major salivary gland carcinoma · malignant glioma · MALT lymphoma · mast cell leukemia · melanoma · metastatic neoplasm · nasopharyngeal carcinoma · nasopharyngeal squamous cell carcinoma · neuroendocrine neoplasm · nodal marginal zone B-cell lymphoma · non-small cell lung carcinoma · ovarian carcinoma · ovarian sarcoma · pancreatic acinar cell carcinoma · pancreatic adenocarcinoma · pancreatic ductal adenocarcinoma · pancreatic neoplasm · peripheral T-cell lymphoma, not otherwise specified · post-transplant lymphoproliferative disease · primary cutaneous B-cell lymphoma · primary peritoneal carcinoma · progesterone-receptor negative breast cancer · prolymphocytic leukemia · prostate cancer · prostate carcinoma · rectal cancer · rectal signet ring cell adenocarcinoma · rectum mucinous adenocarcinoma · renal cell adenocarcinoma · renal cell carcinoma · salivary gland adenoid cystic carcinoma · T-cell large granular lymphocyte leukemia · testicular lymphoma · small cell lung carcinoma · thymic carcinoma
Investigated by: National Cancer Institute (NCI) · Merck Sharp & Dohme LLC · Memorial Sloan Kettering Cancer Center · Vanderbilt-Ingram Cancer Center · AstraZeneca · Beth Israel Deaconess Medical Center
+13 more
· Brigham and Women's Hospital · Centre Leon Berard · Chinese University of Hong Kong · Dana-Farber Cancer Institute · GlaxoSmithKline · M.D. Anderson Cancer Center · Massachusetts General Hospital · National Cancer Institute, France · National Taiwan University Hospital · Novartis · QuantumLeap Healthcare Collaborative · University of California, Los Angeles · University of California, San Francisco

Trials 47

today NCT01802320 · Ph 2 NCT01783171 · Ph 1 NCT01859182 · Ph 2 NCT01705340 · Ph 1 NCT01658943 · Ph 2 NCT01604772 · Ph 2 NCT01519427 · Ph 2 NCT01481129 · Ph 2 NCT01480154 · Ph 1 NCT01466868 · Ph 2 NCT01369849 · Ph 1/2 NCT01370070 · Ph 2 NCT01248247 · Ph 2 NCT01344031 · Ph 1 NCT01349933 · Ph 2 NCT01283035 · Ph 2 NCT01425879 · Ph 2 NCT01319539 · Ph 2 NCT01251861 · Ph 2 NCT01277757 · Ph 2 NCT01333475 · Ph 2 NCT01307631 · Ph 2 NCT01235897 · Ph 1 NCT01295632 · Ph 1 NCT01294306 · Ph 2 NCT01240941 · Ph 2 NCT01239342 · Ph 2 NCT01260701 · Ph 2 NCT01231919 · Ph 1 NCT01281163 · Ph 1 NCT01263145 · Ph 1 NCT01239355 · Ph 2 NCT01258998 · Ph 2 NCT01243762 · Ph 1 NCT01245205 · Ph 1 NCT01253447 · Ph 2 NCT01147211 · Ph 1 NCT01186705 · Ph 2 NCT01169649 · Ph 2 NCT01042379 · Ph 2 NCT01071018 · Ph 1 NCT01021748 · Ph 1 NCT00963547 · Ph 1 NCT00848718 · Ph 1 NCT00670488 · Ph 1

200820092010201120122013201420152016201720182019202020212022202320242025202620272028202920302031

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 118 trials
Phase 1	NCT01783171	Jan 2013 → Jul 2016	pancreatic adenocarcinoma	National Cancer Institute (NCI)	Completed	No outcome recorded
Phase 1	NCT01705340	Sep 2012 → May 2013	HER2 positive breast carcinoma, esophageal cancer, gastric cancer, gastroesophageal junction adenocarcinoma +1	National Cancer Institute (NCI)	Terminated	No outcome recorded
Phase 1	NCT01480154	Nov 2011 → Feb 2020 overdue	cutaneous melanoma, prostate cancer, renal cell adenocarcinoma	National Cancer Institute (NCI)	Active not recruiting	No outcome recorded
Phase 1	NCT01344031	Apr → Jul 2011	estrogen-receptor positive breast cancer, invasive breast carcinoma	National Cancer Institute (NCI)	Completed	No outcome recorded
Phase 1	NCT01235897	Mar 2011 → Mar 2013	cancer	University of California, San Francisco	Completed	No outcome recorded
Phase 1	NCT01295632	Feb 2011 → Dec 2013	cancer of unknown primary site	Merck Sharp & Dohme LLC	Completed	No outcome recorded
Phase 1	NCT01263145	Jan 2011 → Oct 2012	breast carcinoma	National Cancer Institute (NCI)	Completed	No outcome recorded
Phase 1	NCT01231919	Jan 2011 → Apr 2013	Burkitt lymphoma, CD4+/CD56+ hematodermic neoplasm, Hodgkins lymphoma, Waldenstrom macroglobulinemia +24	National Cancer Institute (NCI)	Completed	No outcome recorded
Phase 1	NCT01281163	Jan 2011 → Dec 2013	HER2 positive breast carcinoma, estrogen-receptor negative breast cancer, estrogen-receptor positive breast cancer, progesterone-receptor negative breast cancer +1	National Cancer Institute (NCI)	Terminated	No outcome recorded
Phase 1	NCT01243762	Nov 2010 → Dec 2012	cancer	Merck Sharp & Dohme LLC	Terminated	No outcome recorded Stop: Business
Phase 1	NCT01245205	Nov 2010 → Aug 2014	HER2 positive breast carcinoma, male breast carcinoma	National Cancer Institute (NCI)	Completed	No outcome recorded
Phase 1	NCT01147211	Sep 2010 → Jul 2013	non-small cell lung carcinoma	National Taiwan University Hospital	Unknown	No outcome recorded
Phase 1	NCT01071018	Feb 2010 → Sep 2011	cancer	Merck Sharp & Dohme LLC	Completed	No outcome recorded
Phase 1	NCT01021748	Nov 2009 → Nov 2012	—	Merck Sharp & Dohme LLC	Completed	No outcome recorded
Phase 1	NCT00963547	Sep 2009 → Aug 2011	breast cancer	Merck Sharp & Dohme LLC	Terminated	No outcome recorded
Phase 1	NCT00848718	Mar 2009 → May 2011	—	Merck Sharp & Dohme LLC	Completed	No outcome recorded
Phase 1	NCT00670488	Apr 2008 → Jul 2011	cancer, metastatic neoplasm	Merck Sharp & Dohme LLC	Completed	No outcome recorded
Phase 1	NCT01240928	—	breast cancer	Vanderbilt-Ingram Cancer Center	Withdrawn	No outcome recorded Stop: Enrollment

Phase 1/21 trial
Phase 1/2	NCT01369849	Sep 2011 → Feb 2014	chronic lymphocytic leukemia/small lymphocytic lymphoma	National Cancer Institute (NCI)	Completed	No outcome recorded
Phase 228 trials · 4 missed
Phase 2	NCT01802320	Mar 2013 → Jun 2015	colon mucinous adenocarcinoma, colon signet ring cell adenocarcinoma, rectal signet ring cell adenocarcinoma, rectum mucinous adenocarcinoma	National Cancer Institute (NCI)	Completed	No outcome recorded
Phase 2	NCT01859182	Jan → May 2013	cholangiocarcinoma, gallbladder adenocarcinoma, gallbladder adenosquamous carcinoma	National Cancer Institute (NCI)	Withdrawn	No outcome recorded
Phase 2	NCT01658943	Aug 2012 → Jun 2015	pancreatic acinar cell carcinoma, pancreatic ductal adenocarcinoma	National Cancer Institute (NCI)	Completed	Missed primary
Phase 2	NCT01604772	Jul 2012 → Oct 2013	major salivary gland carcinoma, salivary gland adenoid cystic carcinoma	National Cancer Institute (NCI)	Completed	Missed primary
Phase 2	NCT01519427	Jan 2012 → May 2013	melanoma	National Cancer Institute (NCI)	Terminated	No outcome recorded Stop: Enrollment
Phase 2	NCT01481129	Dec 2011 → Jun 2013	diffuse large B-cell lymphoma	National Cancer Institute (NCI)	Completed	No outcome recorded
Phase 2	NCT01466868	Nov 2011 → Sep 2013	diffuse large B-cell lymphoma	Centre Leon Berard	Terminated	No outcome recorded
Phase 2	NCT01370070	Jul 2011 → Dec 2016	nasopharyngeal carcinoma	Chinese University of Hong Kong	Completed	No outcome recorded
Phase 2	NCT01248247	Jun 2011 → Nov 2020	lung cancer	M.D. Anderson Cancer Center	Completed	No outcome recorded
Phase 2	NCT01349933	Apr 2011 → Oct 2013	nasopharyngeal squamous cell carcinoma	National Cancer Institute (NCI)	Completed	No outcome recorded
Phase 2	NCT01283035	Apr 2011 → Dec 2014	fallopian tube carcinoma, ovarian carcinoma, ovarian sarcoma, primary peritoneal carcinoma	National Cancer Institute (NCI)	Completed	No outcome recorded
Phase 2	NCT01425879	Apr 2011 → May 2013	adult hepatocellular carcinoma, distal biliary tract carcinoma, gallbladder carcinoma	National Cancer Institute (NCI)	Completed	No outcome recorded
Phase 2	NCT01319539	Apr 2011 → Jul 2013	HER2 positive breast carcinoma, estrogen-receptor positive breast cancer, female breast carcinoma, progesterone-receptor positive breast cancer +1	National Cancer Institute (NCI)	Terminated	No outcome recorded
Phase 2	NCT01251861	Mar 2011 → Jul 2018	prostate carcinoma	National Cancer Institute (NCI)	Completed	Missed primary
Phase 2	NCT01277757	Mar 2011 → Aug 2014	breast carcinoma	National Cancer Institute (NCI)	Completed	No outcome recorded
Phase 2	NCT01333475	Mar 2011 → Nov 2013	colorectal neoplasm	National Cancer Institute (NCI)	Completed	No outcome recorded
Phase 2	NCT01307631	Mar 2011 → Sep 2015	endometrial adenosquamous carcinoma, endometrial clear cell adenocarcinoma, endometrial serous adenocarcinoma	National Cancer Institute (NCI)	Completed	No outcome recorded
Phase 2	NCT01294306	Feb 2011 → Aug 2015	adenosquamous lung carcinoma, lung adenocarcinoma, lung large cell carcinoma	National Cancer Institute (NCI)	Completed	No outcome recorded
Phase 2	NCT01240941	Feb 2011 → Jun 2012	breast cancer	Vanderbilt-Ingram Cancer Center	Withdrawn	No outcome recorded Stop: Business
Phase 2	NCT01239342	Jan 2011 → Sep 2018	renal cell carcinoma	National Cancer Institute (NCI)	Terminated	No outcome recorded
Phase 2	NCT01260701	Jan 2011 → May 2014	diffuse gastric adenocarcinoma, gastric intestinal type adenocarcinoma, gastroesophageal junction adenocarcinoma	National Cancer Institute (NCI)	Completed	Missed primary
Phase 2	NCT01239355	Dec 2010 → Feb 2013	adult hepatocellular carcinoma	National Cancer Institute (NCI)	Terminated	No outcome recorded
Phase 2	NCT01258998	Dec 2010 → Jul 2014	B-cell adult acute lymphocytic leukemia, Hodgkins lymphoma, MALT lymphoma, T-cell adult acute lymphocytic leukemia +20	National Cancer Institute (NCI)	Completed	No outcome recorded
Phase 2	NCT01253447	Oct 2010 → Oct 2013	acute erythroid leukemia, acute megakaryoblastic leukemia in adult, acute myeloblastic leukemia with maturation, acute myeloblastic leukemia without maturation +8	National Cancer Institute (NCI)	Completed	No outcome recorded
Phase 2	NCT01186705	Aug 2010 → Aug 2011	colon carcinoma, rectal cancer	Memorial Sloan Kettering Cancer Center	Terminated	No outcome recorded Stop: Enrollment
Phase 2	NCT01169649	Jul 2010 → Feb 2014	neuroendocrine neoplasm, pancreatic neoplasm	Memorial Sloan Kettering Cancer Center	Completed	No outcome recorded
Phase 2	NCT01042379	Mar 2010 → Dec 2030 expected	HER2 positive breast carcinoma, angiosarcoma, female breast carcinoma, hormone receptor-positive breast cancer +1	QuantumLeap Healthcare Collaborative	Recruiting	No outcome recorded
Phase 2	NCT01249105	—	malignant glioma	Dana-Farber Cancer Institute	Withdrawn	No outcome recorded Stop: Business

Comparator or background therapy1 trial
Phase 2	NCT01306045 Comparator	Feb 2011 → Feb 2014	non-small cell lung carcinoma, small cell lung carcinoma, thymic carcinoma	National Cancer Institute (NCI)	Completed	No outcome recorded

Evidence & citations 7 cited values

Every value below carries the sentence it was read from. 53 sources stand behind the page.

Field	Value	Cited text
Known as	MK-2206	“To assess the activity of MK-2206 (Akt inhibitor MK2206) in patients with recurrent or persistent endometrial cancer classified by phosphoinositide-3-kinase catalytic alpha...” NCT01307631 ↗ 55 “We conducted a phase II trial with an allosteric AKT inhibitor MK-2206 in patients with advanced breast cancer who had tumors with PIK3CA/AKT1 mutations and/or PTEN loss/mutation.” PMID 31277699 ↗ Jul 2019 “MK-2206 was administered orally at 200 mg once weekly in 28-d cycles up to 12 cycles in the absence of progression or significant toxicity.” PMID 26213141 ↗ Jul 2015 “Preclinical and early clinical evaluation of the oral AKT inhibitor, MK-2206, for the treatment of acute myelogenous leukemia.” PMID 24583795 ↗ Feb 2014 “MK-2206 is a potent, orally active, allosteric inhibitor of human AKT1, AKT2, and AKT3 with preclinical anti-tumor activity.” NCT01147211 ↗ “Patients with progressive, incurable ACC were enrolled and received MK-2206 150 mg weekly; escalation to 200 mg was allowed.” PMID 37947157 ↗ Nov 2023 “MK-2206 is an oral drug (taken by mouth) that turns off a protein called AKT inside cancer cells.” NCT01235897 ↗ “Phase 2 study of MK-2206, an allosteric inhibitor of AKT, as second-line therapy” PMID 25827820 ↗ Mar 2015 “MK-2206 is an orally selective allosteric inhibitor of AKT developed by MERCK” NCT01466868 ↗ “arm-B received AKT inhibitor MK-2206 200 mg 2x/week” PMID 41609418 ↗ Jan 2026 “MK-2206 (Akt inhibitor MK-2206)” NCT01859182 ↗ Show 45 more sources
Action	Inhibit	“MK-2206 is a potent, oral allosteric inhibitor of all AKT isoforms with antitumor activity in preclinical models.” PMID 22025163 ↗ Oct 2011
Modality	Small molecule	— CHEMBL1079175 ↗
Route	Oral	“MK-2206 administered as an oral formulation” NCT00670488 ↗
Target	AKT1	“allosteric inhibitor of human AKT1, AKT2, and AKT3” NCT01147211 ↗
Target	AKT2	“allosteric inhibitor of human AKT1, AKT2, and AKT3” NCT01147211 ↗
Target	AKT3	“allosteric inhibitor of human AKT1, AKT2, and AKT3” NCT01147211 ↗